THE INDUSTRY’S LARGEST MARKETPLACE FOR PHARMACEUTICALS
steroidify.xyz has been in operation for almost 30 years, acquiring 50’s of thousands of satisfied customers.
steroidify.xyz works very hard to establish trust with our customer. Our high-quality products and professional staff is testament to the legitimacy of our business practice.
Each brand is hand-selected and goes through a very thorough review process.
Quality is held in a very high regard at steroidify.xyz. To further legitimize these products, we do have a comprehensive
Featured
Dropoetin 3000IU
CLASSIFICATION Glycoprotein Cytokine ACNE No WATER RETENTION No HBR No HEPATOTOXICITY No ..
Anafranil 10
ACTIVE HALF-LIFE 6 hours CLASSIFICATION Tricyclic Antidepressant DOSAGE Recommended daily dosage: 10-25 mg A..
Ultima-Hexarelin 2mg
MANUFACTURER Ultima Pharmaceuticals - USA WAREHOUSE USA Warehouse 5 SUBSTANCE Examorelin For your privacy, products are shipped with..
Evista 60
ACTIVE HALF-LIFE 24 hours CLASSIFICATION Selective Estrogen Receptor Modulator (SERM) ACNE None WATER RET..
Halo 10
ACTIVE HALF-LIFE 9 Hours CLASSIFICATION Anabolic Steroid DOSAGE Men 10-40 mg/day ACNE Yes WATER RET..
Ultima-Superdrol
ACTIVE HALF-LIFE 8-12 hours CLASSIFICATION Anabolic Steroid DOSAGE 10-20 mg/day ACNE Rarely WATER..
Ultima-CJC1295 2mg
MANUFACTURER Ultima Peptides WAREHOUSE International Warehouse 3 SUBSTANCE GHRH Peptide Discover the power of CJC-1295, a cu..
Quant-Equipoise 300
ACTIVE HALF-LIFE 14 days CLASSIFICATION Anabolic Steroid DOSAGE Recommended for men: 400-1000 mg/week ACNE Rare occu..
Ultima-Deca 500
ACTIVE HALF-LIFE 6-7 days CLASSIFICATION Anabolic Steroid DOSAGE Men: 300-600 mg/week ACNE Rarely Occurs WATER..
Pharma MIX 1
ACTIVE HALF-LIFE 14 days CLASSIFICATION Anabolic Steroid DOSAGE Men 450-900 mg/week ACNE Yes W..
Eli-20
ACTIVE HALF-LIFE 24-36 Hours CLASSIFICATION PDE5 Inhibitor DOSAGE Men: 10-20mg/day ACNE No WATE..
Pain O Soma 500 mg
PRODUCT CLASSIFICATION Centrally Acting Muscle Relaxant MANUFACTURER HAB Pharma WAREHOUSE LOCATION International Ware..












